Gilead settles Biktarvy patent litigations; no generic entry expected before April 1, 2036

GILEAD SCIENCES, INC.

Settlements with Lupin, Cipla, and Laurus Labs resolve patent disputes over generic Biktarvy.
No generic version of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) permitted in US before April 1, 2036.
Agreements are subject to standard acceleration provisions.
Biktarvy is Gilead's leading HIV treatment; extending exclusivity protects significant revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.